Drug Database · Clinicians

Entrectinib

Brands (1) RozlytrekShow all

Antineoplastic agent; Antineoplastic (protein kinase inhibitor) PH FDA category

Rx · Prescription drug2 PH productsVAT-exempt (some products)
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID c7c71b0c-2549-4495-86b6-c2807fa54908, version date October 8, 2026 (Rozlytrek · Genentech, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
  • Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE ROZLYTREK is a kinase inhibitor indicated for the treatment of: Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (1.1) Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (1.2) 1.1 ROS1 -Positive Non-Small Cell Lung Cancer ROZLYTREK is indicated for the treatment of adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. 1.2 NTRK Gene Fusion-Positive Solid Tumors ROZLYTREK is indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Contraindications

4 CONTRAINDICATIONS None. None. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Select patients for treatment based on the presence of ROS1 rearrangement(s) or NTRK gene fusion. (2.1)
  • Evaluate left ventricular ejection fraction, serum uric acid levels, QRS, and QTc interval and electrolytes prior to ROZLYTREK initiation. (2.2)
  • Select appropriate dosage form: oral capsules, capsules prepared as an oral suspension or oral pellets. (2.3)
  • Use capsules prepared as suspension for enteral tube administration. Do not use pellets for enteral tube administration. (2.3)
  • Administer ROZLYTREK capsules, capsules prepared as a suspension, or pellets once daily, with or without food. (2.4)
  • Adult Dosage for ROS1- Positive Non-Small Cell Lung Cancer: 600 mg orally once daily. (2.5)
  • Adult and Pediatric Dosage for NTRK Gene Fusion-Positive Solid Tumors: Adults: 600 mg orally once daily. (2.6)
  • Pediatric Patients: Recommended dosage is based on age and body surface area (BSA) as shown below. (2.6)
  • Age Recommended Daily Dosage >6 months ≤0.50 m²: 300 mg/m 2 0.51 to 0.80 m²: 200 mg 0.81 to 1.10 m²: 300 mg 1.11 to 1.50 m²: 400 mg BSA ≥1.51 m²: 600 mg once daily >1 month to ≤6 months 250 mg/m 2 once daily Modify dosage of ROZLYTREK if coadministration with moderate or strong CYP3A inhibitors cannot be avoided. (2.8)
  • See preparation and administration instructions. (2.9)
2.1 Patient Selection

2.1 Patient Selection Select patients for the treatment of metastatic NSCLC with ROZLYTREK based on the presence of ROS1 rearrangement(s) in tumor or plasma specimens [see Clinical Studies (14.1)]. Testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing. Information on FDA-approved tests for the detection of ROS1 rearrangement(s) in NSCLC is available at http://www.fda.gov/CompanionDiagnostics.

Select patients for treatment of locally advanced or metastatic solid tumors with ROZLYTREK based on the presence of a NTRK gene fusion in tumor or plasma specimens [see Clinical Studies (14.2)]. Testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing. Information on FDA-approved tests for the detection of NTRK gene fusion(s) in solid tumors is available at http://www.fda.gov/CompanionDiagnostics.

2.2 Recommended Evaluation and Testing

2.2 Recommended Evaluation and Testing Before Initiating ROZLYTREK Before initiating ROZLYTREK, evaluate: Left ventricular ejection fraction (LVEF) [see Warnings and Precautions (5.1)] QRS and QTc intervals and electrolytes [see Warnings and Precautions (5.2)] Serum uric acid levels [see Warnings and Precautions (5.6)]

2.3 ROZLYTREK Dosage Form Overview

2.3 ROZLYTREK Dosage Form Overview The physician should prescribe the most appropriate dosage form of ROZLYTREK according to the dose required and patient needs. ROZLYTREK is available in two dosage forms, and can be administered either as capsules swallowed whole, capsules made into an oral suspension (or for enteral tube administration) and as oral pellets swallowed with soft food.

ROZLYTREK Capsules 100 mg and 200 mg Whole capsules: For patients who can swallow whole capsules and whose doses are multiples of 100 mg. Capsules prepared as an oral suspension: For patients who have difficulty or are unable to swallow capsules or who require enteral administration (e.g., gastric or nasogastric tube). [see Dosage and Administration (2.9)].

For dose increments of 10 mg, only use capsules prepared as a suspension. ROZLYTREK Oral Pellets 50 mg per packet Pellets sprinkled on one or more spoonfuls of soft food: For patients who have difficulty or are unable to swallow capsules but can swallow soft food and whose doses are multiples of 50 mg. [see Dosage and Administration (2.7)].

Do not use pellets for preparation of suspension. Do not attempt to use partial quantities of pellets from 50 mg pellet packets to prepare a dose. Do not use the pellet formulation for enteral tube administration as the pellets may clog the tube.

2.4 ROZLYTREK Administration Overview

2.4 ROZLYTREK Administration Overview Administer ROZLYTREK capsules, capsules prepared as a suspension, or pellets once daily, with or without food. If a dose of ROZLYTREK is missed, make up that dose unless the next dose is due within 12 hours. If vomiting occurs immediately after taking a dose of ROZLYTREK, repeat that dose.

2.5 ROZLYTREK Recommended Dosage for ROS1

2.5 ROZLYTREK Recommended Dosage for ROS1 -Positive Non-Small Cell Lung Cancer The recommended dosage of ROZLYTREK is 600 mg orally once daily with or without food until disease progression or unacceptable toxicity.

2.6 ROZLYTREK Recommended Dosage for NTRK Gene Fusion-Positive Solid Tumors

2.6 ROZLYTREK Recommended Dosage for NTRK Gene Fusion-Positive Solid Tumors The recommended dosages of ROZLYTREK for the treatment of adult and pediatric patients with NTRK Gene Fusion-Positive Solid Tumors are provided in Table 1. Administer the recommended dosage of ROZLYTREK capsules and oral pellets with or without food until disease progression or unacceptable toxicity.

Sprinkle ROZLYTREK oral pellets on one or more spoonfuls of soft food as a vehicle. Table 1. Recommended dosage for Adults and Pediatric patients for the Treatment of NTRK Gene Fusion-Positive Solid Tumors Patient Population Recommended Dosage of ROZLYTREK Duration of Treatment Adults Pediatric patients with BSA ≥ 1.51 m²: 600 mg orally once daily Until disease progression or unacceptable toxicity.

Pediatric patients > 6 months: see Table 2 Pediatric patients > 1 month to ≤ 6 months: 250 mg/m 2 orally once daily To enable dosing increments of 10 mg, capsules prepared as an oral suspension must be used [see Dosage and Administration (2.9)]. The recommended dosages of ROZLYTREK for the treatment of pediatric patients older than 6 months with NTRK Gene Fusion-Positive Solid Tumors is provided in Table 2.

Table 2. Recommended dosage for Pediatric Patients Older than 6 Months for the Treatment of NTRK Gene Fusion-Positive Solid Tumors Body Surface Area (BSA) BSA categories and recommended dosage above are based on closely matching exposures to a target dose of 300 mg/m 2 Recommended Dosage Orally Once Daily ≤0.50 m² 300 mg/m 2 To enable dosing increments of 10 mg, capsules prepared as an oral suspension must be used [see Dosage and Administration (2.9)]. 0.51 to 0.80 m² 200 mg 0.81 to 1.10 m² 300 mg 1.11 to 1.50 m² 400 mg ≥ 1.51 m² 600 mg

2.7 ROZLYTREK Dosage Modifications for Adverse Reactions

2.7 ROZLYTREK Dosage Modifications for Adverse Reactions The recommended dosage reductions of ROZLYTREK for the management of adverse reactions for adults and pediatric patients are provided in Table 3. Table 3. Recommended Dose Reductions for ROZLYTREK for the Management of Adverse Reactions Starting Dose once daily First dose reduction Second dose reduction 250 mg/m 2 or 300 mg/m 2 Reduce the once daily dose to two thirds of the starting dose To enable dosing increments of 10 mg, capsules prepared as an oral suspension must be used [see Dosage and Administration (2.9)].

Reduce the once daily dose to one third of the starting dose Permanently discontinue ROZLYTREK in patients who are unable to tolerate ROZLYTREK after two dose reductions. 200 mg 150 mg once daily 100 mg once daily 300 mg 200 mg once daily 100 mg once daily 400 mg 300 mg once daily 200 mg once daily 600 mg 400 mg once daily 200 mg once daily Table 4 provides the ROZLYTREK recommended dosage modifications for the management of adverse reactions. Table 4.

ROZLYTREK Dosage Modifications for the Management of Adverse Reactions Adverse Reaction Severity Severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. Dosage Modification Congestive Heart Failure [see Warnings and Precautions (5.1)] Grade 2 or 3 Withhold ROZLYTREK until recovered to less than or equal to Grade 1.

Resume at reduced dose. Grade 4 Permanently discontinue ROZLYTREK. QRS or QTc Interval Prolongation [see Warnings and Precautions (5.2)] QRS > 120 ms OR QTc > 500 ms Withhold ROZLYTREK until QRS or QTc interval recovers to baseline. Resume at same dose if factors that caused QRS or QTc prolongation are identified and corrected.

Resume at reduced dose if other factors that cause QRS or QTc prolongation have not been identified. Ventricular tachycardia (Grade 3 or 4); signs/symptoms of serious arrhythmia; or Brugada syndrome Permanently discontinue ROZLYTREK. Central Nervous System Effects [see Warnings and Precautions (5.3)] Intolerable Grade 2 Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline.

Resume at same dose or reduced dose, as clinically appropriate. Grade 3 Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline. Resume at reduced dose. Grade 4 Permanently discontinue ROZLYTREK. Hepatotoxicity [see Warnings and Precautions (5.5)] Grade 3 Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline.

Resume at same dose if resolution occurs within 4 weeks. Permanently discontinue if adverse reaction does not resolve within 4 weeks. Resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks. Grade 4 Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline. Resume at reduced dose if resolution occurs within 4 weeks.

Permanently discontinue if adverse reaction does not resolve within 4 weeks. Permanently discontinue for recurrent Grade 4 events. ALT or AST greater than 3 times ULN with concurrent total bilirubin greater than 1.5 times ULN (in the absence of cholestasis or hemolysis). Permanently discontinue ROZLYTREK. Hyperuricemia [see Warnings and Precautions (5.6)] Symptomatic or Grade 4 Initiate urate-lowering medication.

Withhold ROZLYTREK until improvement of signs or symptoms. Resume ROZLYTREK at same or reduced dose. Vision Disorders [see Warnings and Precautions (5.7)] Grade 2 or above Withhold ROZLYTREK until improvement or stabilization. Resume at same dose or reduced dose, as clinically appropriate. Anemia or Neutropenia [see Adverse Reactions (6.1)] Grade 3 or 4 Withhold ROZLYTREK until recovery to less than or equal to Grade 2.

Resume at the same dose or reduced dose, as clinically appropriate. Other Adverse Reactions [see Adverse Reactions (6.1)] Grade 3 or 4 Withhold ROZLYTREK until adverse reaction resolves or improves to recovery or improvement to Grade 1 or baseline. Resume at the same or reduced dose if resolution occurs within 4 weeks. Permanently discontinue if adverse reaction does not resolve within 4 weeks.

Permanently discontinue for recurrent Grade 4 events.

2.8 ROZLYTREK Dosage Modifications for Drug Interactions Moderate and Strong CYP3A Inhibitors…

2.8 ROZLYTREK Dosage Modifications for Drug Interactions Moderate and Strong CYP3A Inhibitors Adults and Pediatric Patients 2 Years and Older Avoid coadministration of ROZLYTREK with moderate or strong CYP3A inhibitors. If coadministration cannot be avoided, reduce the ROZLYTREK dose as shown in Table 5 and limit coadministration to 14 days or less.

Table 5. Recommended Dose Modifications of ROZLYTREK for Concomitant Use with Moderate or Strong CYP3A Inhibitors for Adults and Pediatric Patients 2 Years and Older Starting dose For pediatric patients with a starting dose less than 200 mg, avoid coadministration with moderate or strong CYP3A inhibitors Moderate CYP3A inhibitor Strong CYP3A inhibitor 200 mg 50 mg once daily 50 mg on alternate days 300 mg 100 mg once daily 50 mg once daily 400 mg 200 mg once daily 50 mg once daily 600 mg 200 mg once daily 100 mg once daily After discontinuation of a strong or moderate CYP3A inhibitor for 3 to 5 elimination half-lives, resume the ROZLYTREK dose that was taken prior to initiating the CYP3A inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].

2.9 ROZLYTREK Preparation and Administration Instructions

2.9 ROZLYTREK Preparation and Administration Instructions ROZLYTREK Capsules Swallow capsules whole. Do not crush or chew the capsules. ROZLYTREK Capsules Prepared as a Suspension for Oral or Enteral Tube Administration It is recommended that a healthcare provider discuss with the patient or caregiver, the volume of water or milk to be added and oral suspension to withdraw, prior to administration of the first dose (see Table 6).

Table 6 provides the ROZLYTREK dose and volume of room temperature drinking water or milk required to prepare an oral suspension. Instruct patients or caregivers to carefully open capsule(s) and pour the contents into room temperature drinking water or milk to prepare an oral suspension. Let sit for 15 minutes. Table 6. Preparation of ROZLYTREK Capsules as an Oral Suspension Dose of ROZLYTREK to be administered Dose needed for suspension (using 100 mg or 200 mg capsules, as appropriate) Volume of water or milk to be added Volume of oral suspension to withdraw and administer 20 mg 100 mg 5 mL 1 mL 30 mg 100 mg 5 mL 1.5 mL 40 mg 100 mg 5 mL 2 mL 50 mg 100 mg 5 mL 2.5 mL 60 mg 100 mg 5 mL 3 mL 70 mg 100 mg 5 mL 3.5 mL 80 mg 100 mg 5 mL 4 mL 90 mg 100 mg 5 mL 4.5 mL 100 mg 100 mg 5 mL 5 mL 110 mg 200 mg 10 mL 5.5 mL 120 mg 200 mg 10 mL 6 mL 130 mg 200 mg 10 mL 6.5 mL 140 mg 200 mg 10 mL 7 mL 150 mg 200 mg 10 mL 7.5 mL 200 mg 200 mg 10 mL 10 mL 300 mg 300 mg 15 mL 15 mL 400 mg 400 mg 20 mL 20 mL 600 mg 600 mg 30 mL 30 mL Administer ROZLYTREK oral suspension immediately after preparation.

Discard any unused suspension if not used within 2 hours. Instruct patients to drink water after taking the oral suspension to ensure ROZLYTREK has been completely swallowed. Enteral Tube Administration If enteral administration (e.g., gastric or nasogastric tube) is required, administer the oral suspension via the tube.

Use an enteral tube that is 8 FR or higher to administer dosing volumes of 3 mL or higher. Instruct patients to divide dosing volumes of 3 mL or higher into at least two aliquots and flush the tube after each administration. Flush the tube with a volume of water or milk that is equal to the aliquot administered. For a dose volume of 30 mL, divide into at least three (10 mL) aliquots.

The tube should be flushed with water or milk after delivering each aliquot of ROZLYTREK. Refer to the Instructions for Use for detailed instructions on preparation and administration of ROZLYTREK capsules as an oral suspension via an enteral tube. ROZLYTREK Oral Pellets Sprinkle pellets on one or more spoonfuls of a soft food (e.g., applesauce, yogurt, or pudding) and take within 20 minutes of preparation.

Do not crush or chew to avoid a bitter taste. The patient should drink water after taking the pellets to ensure the drug has been completely swallowed. Do not attempt to use partial quantities of pellets from 50 mg pellet packets to prepare a dose. Do not use the pellet formulation for enteral tube administration as the pellets may clog the tube.

Refer to the Instructions for Use for detailed instructions on preparation and administration of ROZLYTREK oral pellets.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations)

8.6 Renal Impairment No dose adjustment is recommended for patients with mild or moderate renal impairment (CLcr 30 to < 90 mL/min calculated by Cockcroft-Gault equation). ROZLYTREK has not been studied in patients with severe renal impairment (CLcr < 30 mL/min) [see Clinical Pharmacology (12.3)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment The effect of moderate hepatic impairment (total bilirubin > 1.5 – 3.0 times ULN with any aspartate aminotransferase) or severe hepatic impairment (total bilirubin >3.0 times ULN with any aspartate aminotransferase) on the safety of ROZLYTREK at the recommended dosage is unknown. Consider the risk-benefit profile of ROZLYTREK prior to determining whether to administer ROZLYTREK to patients with moderate to severe hepatic impairment.

Monitor for ROZLYTREK adverse reactions in patients with hepatic impairment more frequently since these patients may be at increased risk for adverse reactions [see Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of ROZLYTREK have been established in pediatric patients older than 1 month of age [see Clinical Studies (14.2)]. Use of ROZLYTREK in these age groups is supported by evidence from adequate and well-controlled studies of ROZLYTREK in adults and pediatric patients with additional population pharmacokinetic data demonstrating that the exposure of drug substance in pediatric patients greater than 1 month of age is expected to be in the adult range, and that the course of disease is sufficiently similar in adult and pediatric patients to allow extrapolation of data in adults to pediatric patients.

The safety and effectiveness of ROZLYTREK have not been established in pediatric patients with ROS1 -positive NSCLC. Juvenile Animal Toxicity Data In a 13-week juvenile rat toxicology study, animals were dosed daily from post-natal day 7 to day 97 (approximately equivalent to neonate to adulthood). Entrectinib resulted in: decreased body weight gain and delayed sexual maturation at doses ≥ 4 mg/kg/day (approximately 0.06 times the human exposure (AUC) at the 600 mg dose), deficits in neurobehavioral assessments including functional observational battery and learning and memory (at doses ≥ 8 mg/kg/day, approximately 0.14 times the human exposure at the 600 mg dose), and decreased femur length at doses ≥ 16 mg/kg/day (approximately 0.18 times the human exposure at the 600 mg dose).

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 355 patients who received ROZLYTREK across clinical trials, 25% were 65 years or older, and 5% were 75 years of age or older. Clinical studies of ROZLYTREK did not include sufficient numbers of geriatric patients to determine whether they respond differently from younger patients.

Administration

2.4 ROZLYTREK Administration Overview Administer ROZLYTREK capsules, capsules prepared as a suspension, or pellets once daily, with or without food. If a dose of ROZLYTREK is missed, make up that dose unless the next dose is due within 12 hours. If vomiting occurs immediately after taking a dose of ROZLYTREK, repeat that dose.

2.9 ROZLYTREK Preparation and Administration Instructions ROZLYTREK Capsules Swallow capsules whole. Do not crush or chew the capsules. ROZLYTREK Capsules Prepared as a Suspension for Oral or Enteral Tube Administration It is recommended that a healthcare provider discuss with the patient or caregiver, the volume of water or milk to be added and oral suspension to withdraw, prior to administration of the first dose (see Table 6 ). Table 6 provides the ROZLYTREK dose and volume of room temperature drinking water or milk required to prepare an oral suspension. Instruct patients or caregivers to carefully open capsule(s) and pour the contents into room temperature drinking water or milk to prepare an oral suspension. Let sit for 15 minutes. Table 6. Preparation of ROZLYTREK Capsules as an Oral Suspension Dose of ROZLYTREK to be administered Dose needed for suspension (using 100 mg or 200 mg capsules, as appropriate) Volume of water or milk to be added Volume of oral suspension to withdraw and administer 20 mg 100 mg 5 mL 1 mL 30 mg 100 mg 5 mL 1.5 mL 40 mg 100 mg 5 mL 2 mL 50 mg 100 mg 5 mL 2.5 mL 60 mg 100 mg 5 mL 3 mL 70 mg 100 mg 5 mL 3.5 mL 80 mg 100 mg 5 mL 4 mL 90 mg 100 mg 5 mL 4.5 mL 100 mg 100 mg 5 mL 5 mL 110 mg 200 mg 10 mL 5.5 mL 120 mg 200 mg 10 mL 6 mL 130 mg 200 mg 10 mL 6.5 mL 140 mg 200 mg 10 mL 7 mL 150 mg 200 mg 10 mL 7.5 mL 200 mg 200 mg 10 mL 10 mL 300 mg 300 mg 15 mL 15 mL 400 mg 400 mg 20 mL 20 mL 600 mg 600 mg 30 mL 30 mL Administer ROZLYTREK oral suspension immediately after preparation. Discard any unused suspension if not used within 2 hours. Instruct patients to drink water after taking the oral suspension to ensure ROZLYTREK has been completely swallowed. Enteral Tube Administration If enteral administration (e.g., gastric or nasogastric tube) is required, administer the oral suspension via the tube. Use an enteral tube that is 8 FR or higher to administer dosing volumes of 3 mL or higher. Instruct patients to divide dosing volumes of 3 mL or higher into at least two aliquots and flush the tube after each administration. Flush the tube with a volume of water or milk that is equal to the aliquot administered. For a dose volume of 30 mL, divide into at least three (10 mL) aliquots. The tube should be flushed with water or milk after delivering each aliquot of ROZLYTREK. Refer to the Instructions for Use for detailed instructions on preparation and administration of ROZLYTREK capsules as an oral suspension via an enteral tube. ROZLYTREK Oral Pellets Sprinkle pellets on one or more spoonfuls of a soft food (e.g., applesauce, yogurt, or pudding) and take within 20 minutes of preparation. Do not crush or chew to avoid a bitter taste. The patient should drink water after taking the pellets to ensure the drug has been completely swallowed. Do not attempt to use partial quantities of pellets from 50 mg pellet packets to prepare a dose. Do not use the pellet formulation for enteral tube administration as the pellets may clog the tube. Refer to the Instructions for Use for detailed instructions on preparation and administration of ROZLYTREK oral pellets.

US FDA label

Dosage forms

Philippines

  • Capsule: 100 mg, 200 mg

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Entrectinib as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Entrectinib nib (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

Philippine FDA-registered products for Entrectinib
Package insert
RozlytrekEntrectinib
100 mg CapsuleWhite HDPE Bottle with dessicant and a child-resistant screw cap (Box of 30 capsules)
RxVAT-exempt
Mayne Pharma Inc.USA
Roche (Philippines), Inc.Trader: F. Hoffman-La Roche AG
DR-XY48929
Nov 23, 2028
RozlytrekEntrectinib nibVariant spelling
200 mg CapsuleWhite HDPE Bottle with dessicant and a child-resistant screw cap (Box of 90 capsules)
Rx
Mayne Pharma Inc.USA
Roche (Philippines), Inc.Trader: F. Hoffman-La Roche AG
DR-XY48930
Nov 22, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Capsules: 100 mg: Size 2 yellow opaque body and cap, with "ENT 100" printed in blue ink on body. 200 mg: Size 0 orange opaque body and cap, with "ENT 200" printed in blue ink on body. Pellets: 50 mg: Supplied as brownish orange or grayish orange pellets in packets. Capsules: 100 mg and 200 mg (3) Pellets: 50 mg per packet (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Congestive Heart Failure (CHF): Assess left ventricular ejection fraction (LVEF) prior to initiation of ROZLYTREK. Monitor patients for clinical signs and symptoms of CHF. For patients with myocarditis, with or without a decreased ejection fraction, MRI or cardiac biopsy may be required to make the diagnosis. For new onset or worsening CHF, withhold ROZLYTREK, reassess LVEF and institute appropriate medical management. Reduce dose or permanently discontinue ROZLYTREK based on severity of CHF or worsening LVEF. (2.7, 5.1)
  • Ventricular Arrhythmias: Monitor patients who have or who are at risk for QRS or QTc interval prolongation. Assess QT interval and electrolytes at baseline and periodically during treatment. Withhold and then resume at same or reduced dose, or permanently discontinue ROZLYTREK based on severity. (2.2, 2.7, 5.2)
  • Central Nervous System (CNS) Effects: CNS adverse reactions including cognitive impairment, mood disorders, dizziness, and sleep disturbances can occur with ROZLYTREK. Withhold and then resume at same or reduced dose upon improvement or permanently discontinue ROZLYTREK based on severity. (2.7, 5.3)
  • Skeletal Fractures: ROZLYTREK increases the risk of fractures. Promptly evaluate patients with signs or symptoms of fractures. (5.4)
  • Hepatotoxicity: Monitor liver tests, including ALT and AST, every 2 weeks during the first month of treatment, …
5.1 Congestive Heart Failure

5.1 Congestive Heart Failure Among the 355 patients who received ROZLYTREK across clinical trials, congestive heart failure (CHF) occurred in 3.4% of patients, including Grade 3 (2.3%) [see Adverse Reactions (6.1)]. In clinical trials, baseline cardiac function and routine cardiac monitoring other than electrocardiograms (ECGs) were not conducted and eligibility criteria excluded patients with symptomatic CHF, myocardial infarction, unstable angina, and coronary artery bypass graft within 3 months of study entry.

Among the 12 patients with CHF, the median time to onset was 2 months (range: 11 days to 12 months). ROZLYTREK was interrupted in 6 of these patients (50%) and discontinued in 2 of these patients (17%). CHF resolved in 6 patients (50%) following interruption or discontinuation of ROZLYTREK and institution of appropriate medical management.

In addition, myocarditis in the absence of CHF was documented in 0.3% of patients. Assess left ventricular ejection fraction (LVEF) prior to initiation of ROZLYTREK. Monitor patients for clinical signs and symptoms of CHF, including shortness of breath and edema. For patients with myocarditis, with or without a decreased ejection fraction, MRI or cardiac biopsy may be required to make the diagnosis.

For patients with new onset or worsening CHF, withhold ROZLYTREK, institute appropriate medical management, and reassess LVEF. Based on the severity of CHF or worsening LVEF, resume ROZLYTREK at a reduced dose upon recovery to baseline or permanently discontinue [see Dosage and Administration (2.7)].

5.2 Ventricular Arrhythmias

5.2 Ventricular Arrhythmias Among the 355 patients who received ROZLYTREK across the clinical trials, 3.1% of patients with at least one post-baseline ECG assessment experienced QTc interval prolongation of > 60 ms after starting ROZLYTREK and 0.6% had a QTc interval > 500 ms. Monitor patients who have or are at significant risk of developing QTc interval prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QTc prolongation.

Assess QTc interval and electrolytes prior to initiation of ROZLYTREK and periodically during treatment, adjusting frequency based upon risk factors such as congestive heart failure, electrolyte abnormalities, or concomitant medications known to prolong the QTc interval. Brugada pattern, Brugada syndrome, and ventricular tachycardia have been reported in the postmarketing setting in patients who received ROZLYTREK [see Adverse Reactions (6.2)].

Monitor patients who have or are at significant risk of developing QRS prolongation, including patients with known Brugada syndrome, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QRS prolongation [see Drug Interactions (7.2), Clinical Pharmacology (12.2)]. Based on the severity of QRS or QTc interval prolongation, withhold ROZLYTREK and then resume at same or reduced dose, or permanently discontinue [see Dosage and Administration (2.7)].

5.3 Central Nervous System Effects

5.3 Central Nervous System Effects A broad spectrum of central nervous system (CNS) adverse reactions occurred in patients receiving ROZLYTREK, including cognitive impairment, mood disorders, dizziness, and sleep disturbances. Among the 355 patients who received ROZLYTREK across clinical trials, 96 (27%) experienced cognitive impairment; symptoms occurred within 3 months of starting ROZLYTREK in 74 (77%).

Cognitive impairment included cognitive disorders (8%), confusional state (7%), disturbance in attention (4.8%), memory impairment (3.7%), amnesia (2.5%), aphasia (2.3%), mental status changes (2%), hallucinations (1.1%), and delirium (0.8%). Grade 3 cognitive adverse reactions occurred in 4.5% of patients. Among the 96 patients with cognitive impairment, 13% required a dose reduction, 18% required dose interruption and 1% discontinued ROZLYTREK due to cognitive adverse reactions.

Among the 355 patients who received ROZLYTREK across clinical trials, 36 (10%) experienced mood disorders. The median time to onset of mood disorders was 1 month (range: 1 day to 9 months). Mood disorders occurring in ≥ 1% of patients included anxiety (4.8%), depression (2.8%) and agitation (2%). Grade 3 mood disorders occurred in 0.6% of patients.

One completed suicide was reported 11 days after treatment had ended. Among the 36 patients who experienced mood disorders, 6% required a dose reduction, 6% required dose interruption and no patients discontinued ROZLYTREK due to mood disorders. Dizziness occurred in 136 (38%) of the 355 patients. Among the 136 patients who experienced dizziness, Grade 3 dizziness occurred in 2.2% of patients.

Ten percent of patients required a dose reduction, 7% required dose interruption and 0.7% discontinued ROZLYTREK due to dizziness. Among the 355 patients who received ROZLYTREK across clinical trials, 51 (14%) experienced sleep disturbances. Sleep disturbances included insomnia (7%), somnolence (7%), hypersomnia (1.1%), and sleep disorder (0.3%).

Grade 3 sleep disturbances occurred in 0.6% of patients. Among the 51 patients who experienced sleep disturbances, 6% required a dose reduction and no patients discontinued ROZLYTREK due to sleep disturbances. The incidence of CNS adverse reactions was similar in patients with and without CNS metastases; however, the incidence of dizziness (38% vs 31%), headache (21% vs 13%), paresthesia (20% vs 6%), balance disorder (13% vs 4%), and confusional state (11% vs 2%) appeared to be increased in patients with CNS metastases who had received prior CNS irradiation (n = 90) compared to those who did not (n = 48).

Advise patients and caregivers of these risks with ROZLYTREK. Advise patients not to drive or operate hazardous machinery if they are experiencing CNS adverse reactions. Withhold and then resume at same or reduced dose upon improvement, or permanently discontinue ROZLYTREK based on severity [see Dosage and Administration (2.7)].

5.4 Skeletal Fractures

5.4 Skeletal Fractures ROZLYTREK increases the risk of fractures. In an expanded safety population that included 338 adult patients and 76 pediatric patients who received ROZLYTREK across clinical trials, 5% of adult patients and 25% of pediatric patients experienced fractures [see Use in Specific Population (8.4)]. In adult and pediatric patients, some fractures occurred in the setting of a fall or other trauma to the affected area; in pediatric patients some fractures occurred with no trauma.

In general, there was inadequate assessment for tumor involvement at the site of fracture; however, radiologic abnormalities possibly indicative of tumor involvement were reported in some adult patients. In both adult and pediatric patients, most fractures were hip or other lower extremity fractures (e.g., femoral or tibial shaft).

In two pediatric patients, bilateral femoral neck fractures occurred. A total of 41 fracture events were reported in 19 pediatric patients, with 13 patients who experienced more than one occurrence of fracture. Among the 19 pediatric patients who experienced fractures, 17 patients were less than 12 years of age. Among the 41 fracture events, 27 fracture events resolved, 4 fracture events resolved with sequelae and 3 events were resolving.

The median time to fracture was 3.8 months (range 0.3 to 18.5 months) in adults and 4.3 months (range: 2 months to 28.7 months) in pediatric patients. ROZLYTREK was interrupted in 41% of adults and 16% of pediatric patients who experienced fractures. Five pediatric patients discontinued treatment due to fractures. Promptly evaluate patients with signs or symptoms (e.g., pain, changes in mobility, deformity) of fractures.

There are no data on the effects of ROZLYTREK on healing of known fractures and risk of future fractures.

5.5 Hepatotoxicity

5.5 Hepatotoxicity Among the 355 patients who received ROZLYTREK, increased AST of any grade occurred in 42% of patients and increased ALT of any grade occurred in 36%. Grade 3 – 4 increased AST or ALT occurred in 2.5% and 2.8% of patients, respectively; the incidence may be underestimated as 4.5% of patients had no post-treatment liver function tests [see Adverse Reactions (6.1)].

The median time to onset of increased AST was 2 weeks (range: 1 day to 29.5 months). The median time to onset of increased ALT was 2 weeks (range: 1 day to 9.2 months). Increased AST or ALT leading to dose interruptions or reductions occurred in 0.8% and 0.8% of patients, respectively. ROZLYTREK was discontinued due to increased AST or ALT in 0.8% patients.

Monitor liver tests, including ALT and AST, every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated. Withhold or permanently discontinue ROZLYTREK based on the severity. If withheld, resume ROZLYTREK at the same or reduced dose [see Dosage and Administration (2.7)].

5.6 Hyperuricemia

5.6 Hyperuricemia Among 355 patients who received ROZLYTREK across clinical trials, 32 patients (9%) experienced hyperuricemia reported as adverse reactions with symptoms, as well as elevated uric acid levels. Grade 4 hyperuricemia occurred in 1.7% of patients, including one patient who died due to tumor lysis syndrome.

Among the 32 patients with hyperuricemic adverse reactions, 34% required urate-lowering medication to reduce uric acid levels, 6% required dose reduction and 6% required dose interruption. Hyperuricemia resolved in 73% of patients following initiation of urate-lowering medication without interruption or dose reduction of ROZLYTREK.

No patients discontinued ROZLYTREK due to hyperuricemia. Assess serum uric acid levels prior to initiation of ROZLYTREK and periodically during treatment. Monitor patients for signs and symptoms of hyperuricemia. Initiate treatment with urate-lowering medications as clinically indicated and withhold ROZLYTREK for signs and symptoms of hyperuricemia.

Resume ROZLYTREK at same or reduced dose upon improvement of signs or symptoms based on severity [see Dosage and Administration (2.7)].

5.7 Vision Disorders

5.7 Vision Disorders Among the 355 patients who received ROZLYTREK across clinical trials, vision changes occurred in 21% of patients, including Grade 1 (17%), Grade 2 (2.8%) and Grade 3 (0.8%) [see Adverse Reactions (6.1)]. Vision disorders occurring in ≥ 1% included blurred vision (9%), photophobia (5%), diplopia (3.1%), visual impairment (2%), photopsia (1.1%), cataract (1.1%), and vitreous floaters (1.1%).

For patients with new visual changes or changes that interfere with activities of daily living, withhold ROZLYTREK until improvement or stabilization and conduct an ophthalmological evaluation as clinically appropriate. Upon improvement or stabilization, resume ROZLYTREK at same or reduced dose [see Dosage and Administration (2.7)].

5.8 Embryo-Fetal Toxicity

5.8 Embryo-Fetal Toxicity Based on literature reports in humans with congenital mutations leading to changes in TRK signaling, findings from animal studies, and its mechanism of action, ROZLYTREK can cause fetal harm when administered to a pregnant woman. Administration of entrectinib to pregnant rats resulted in malformations at exposures approximately 2.7 times the human exposure at the 600 mg dose based on area under the curve (AUC).

Advise pregnant women of the potential risk to a fetus. Advise female patients of reproductive potential to use effective contraception during treatment with ROZLYTREK and for 5 weeks following the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ROZLYTREK and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

Drug interactions

Drug interactions (US label) US FDA label
  • Moderate and Strong CYP3A Inhibitors: For adult and pediatric patients 2 years and older, reduce the dose of ROZLYTREK if coadministration of moderate or strong CYP3A inhibitors cannot be avoided. (2.8, 7.1)
  • For pediatric patients less than 2 years, avoid coadministration with ROZLYTREK. (7.1)
  • Moderate and Strong CYP3A Inducers: Avoid coadministration with ROZLYTREK. (7.1)
  • Drugs That Prolong QRS or QTc Interval: Avoid concomitant use with ROZLYTREK. (7.2)
7.1 Effect of Other Drugs

7.1 Effect of Other Drugs on ROZLYTREK Moderate and Strong CYP3A Inhibitors Adults and Pediatric Patients 2 Years and Older Coadministration of ROZLYTREK with a strong or moderate CYP3A inhibitor increases entrectinib plasma concentrations [see Clinical Pharmacology (12.3)], which could increase the frequency or severity of adverse reactions. Avoid coadministration of strong or moderate CYP3A inhibitors with ROZLYTREK.

If coadministration is unavoidable, reduce the ROZLYTREK dose [see Dosage and Administration (2.8), Clinical Pharmacology (12.3)]. Pediatric Patients less than 2 Years Avoid coadministration of ROZLYTREK with moderate or strong CYP3A inhibitors [see Clinical Pharmacology (12.3)]. Avoid grapefruit products during treatment with ROZLYTREK, as they contain inhibitors of CYP3A.

Moderate and Strong CYP3A Inducers Coadministration of ROZLYTREK with a strong or moderate CYP3A inducer decreases entrectinib plasma concentrations [see Clinical Pharmacology (12.3)], which may reduce ROZLYTREK efficacy. Avoid coadministration of strong and moderate CYP3A inducers with ROZLYTREK.

7.2 Drugs That Prolong QRS or QTc Interval

7.2 Drugs That Prolong QRS or QTc Interval QRS prolongation, including Brugada pattern or syndrome, and QTc interval prolongation can occur with ROZLYTREK. Avoid coadministration of ROZLYTREK with other products that can prolong the QRS or QTc interval [see Warnings and Precautions (5.2), Clinical Pharmacology (12.2)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Metabolism Entrectinib is metabolized primarily by CYP3A4 (~76%).

The active metabolite M5 (formed by CYP3A4) is the only major active circulating metabolite identified.

Drug Interaction Studies Clinical Studies Effect of CYP3A Inhibitors on Entrectinib: Coadministration of itraconazole (a strong CYP3A inhibitor) with a single 100 mg dose of ROZLYTREK capsule increased entrectinib AUC 0-INF by 6-fold and C max by 1.7-fold [see Drug Interactions (7.1) ] .

Coadministration of a moderate CYP3A inhibitor with ROZLYTREK capsule is predicted to increase entrectinib AUC 0-Tau by 3-fold and C max by 2.9-fold.

Effect of CYP3A Inducers on Entrectinib: Coadministration of rifampin (a strong CYP3A inducer) with a single 600 mg dose of ROZLYTREK capsule reduced entrectinib AUC 0-INF by 77% and C max by 56% [see Drug Interactions (7.1) ].

Coadministration of a moderate CYP3A inducer with ROZLYTREK capsule is predicted to reduce entrectinib AUC 0-Tau by 56% and C max by 43%.

Effect of Entrectinib on CYP Substrates : Coadministration of 600 mg dose of ROZLYTREK capsule once daily with oral midazolam (a sensitive CYP3A substrate) in patients increased the midazolam AUC by 50% but reduced midazolam C max by 21% [see Drug Interactions (7.1) ] .

Effect of Entrectinib on Transporters: Coadministration of a single 600 mg dose of ROZLYTREK capsule with digoxin [a sensitive P-glycoprotein (P-gp) substrate] increased digoxin C max by 28% and AUC by 18%.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling: Congestive Heart Failure [see Warnings and Precautions (5.1)] Ventricular Arrhythmias [see Warnings and Precautions (5.2)] Central Nervous System Effects [see Warnings and Precautions (5.3)] Skeletal Fractures [see Warnings and Precautions (5.4)] Hepatotoxicity [see Warnings and Precautions (5.5)] Hyperuricemia [see Warnings and Precautions (5.6)] Vision Disorders [see Warnings and Precautions (5.7)] The most common adverse reactions (≥ 20%) were fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, dysesthesia, dyspnea, myalgia, cognitive impairment, increased weight, cough, vomiting, pyrexia, arthralgia, and vision disorders. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trial Experience

6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Data in WARNINGS AND PRECAUTIONS and below reflect exposure to ROZLYTREK in 355 patients, including 172 (48%) patients exposed for 6 months or longer and 84 (24%) patients exposed for 1 year or longer.

ROZLYTREK was studied in one dose-finding trial in adults [ALKA (n = 57)], one dose-finding and activity-estimating trial in adults [STARTRK-1 (n = 76)], one dose-finding and activity-estimating trial in pediatric and adult patients [STARTRK-NG (n = 16)], and one single arm, activity-estimating trial in adults [STARTRK-2 (n = 206)]. The population characteristics were: median age 55 years (range: 4 to 86 years); 5% (n = 17) were less than 18 years of age; 55% were female; and 66% were White, 23% were Asian, and 5% were Black; 3% were Hispanic/Latino.

The most common tumors (≥ 5%) were lung (56%), sarcoma (8%), and colon (5%). ROS1 gene fusions were present in 42% and NTRK gene fusions were present in 20%. Most adults (75%) received ROZLYTREK 600 mg orally once daily. The doses ranged from 100 mg/m 2 to 1600 mg/m 2 once daily in adults and 250 mg/m 2 to 750 mg/m 2 once daily in pediatric patients.

Serious adverse reactions occurred in 39% of patients. The most frequent serious adverse reactions (≥ 2%) were pneumonia (3.9%), dyspnea (3.7%), pleural effusion (3.4%), sepsis (2.5%), pulmonary embolism (2.3%), respiratory failure (2%), and pyrexia (2%). Grade 3 or 4 adverse reactions occurred in 60% of patients; the most common (≥ 2%) were lung infection (5%), increased weight (7%), dyspnea (6%), fatigue/asthenia (5%), cognitive disorders (4.5%), syncope (2.5%), pulmonary embolism (3.4%), hypoxia (3.4%), pleural effusion (3.1%), hypotension (2.8%), diarrhea (2%), and urinary tract infection (2.5%).

Fatal events included dyspnea (0.6%), pneumonia (0.6%), sepsis (0.6%), completed suicide (0.3%), large intestine perforation (0.3%) and tumor lysis syndrome (0.3%). One patient developed Grade 4 myocarditis after one dose of ROZLYTREK which resolved after discontinuation of ROZLYTREK and administration of high-dose corticosteroids.

Permanent discontinuation due to an adverse reaction occurred in 9% of patients who received ROZLYTREK. The most frequent adverse reactions (< 1% each) that resulted in permanent discontinuation were pneumonia, cardio-respiratory arrest, dyspnea, and fatigue. Dose interruptions due to adverse reactions occurred in 46% of patients.

The most frequent adverse reactions (≥ 2%) that resulted in interruption were increased blood creatinine (4%), fatigue (3.7%), anemia (3.1%), diarrhea (2.8%), pyrexia (2.8%), dizziness (2.5%), dyspnea (2.3%), nausea (2.3%), pneumonia (2.3%), cognitive disorder (2%) and neutropenia (2%). Dose reductions due to adverse reactions occurred in 29% of patients who received ROZLYTREK.

The most frequent adverse reactions resulting in dose reductions (≥ 1%) were dizziness (3.9%), increased blood creatinine (3.1%), fatigue (2.3%), anemia (1.7%), and increased weight (1.4%). The most common adverse reactions (≥ 20%) were fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, dysesthesia, dyspnea, myalgia, cognitive impairment, increased weight, cough, vomiting, pyrexia, arthralgia and vision disorders.

Table 7 summarizes the adverse reactions observed in these 355 patients. Table 7. Adverse Reactions (≥ 10%) in Patients Receiving ROZLYTREK in ALKA, STARTRK-1, STARTRK-2, and STARTRK-NG Adverse Reactions ROZLYTREK n = 355 All Grades (%) Grade ≥ 3 Grades 3 – 5, inclusive of fatal adverse reactions, including 2 events of pneumonia and 2 events of dyspnea.

(%) General Fatigue Includes fatigue, asthenia 48 5 Edema Includes face edema, fluid retention, generalized edema, localized edema, edema, edema peripheral, peripheral swelling 40 1.1 Pyrexia 21 0.8 Gastrointestinal Constipation 46 0.6 Diarrhea 35 2.0 Nausea 34 0.3 Vomiting 24 0.8 Abdominal pain Includes abdominal pain upper, abdominal pain, lower abdominal discomfort, abdominal tenderness 16 0.6 Nervous System Dysgeusia 44 0.3 Dizziness Includes dizziness, vertigo, dizziness postural 38 0.8 Dysesthesia Includes paresthesia, hyperesthesia, hypoesthesia, dysesthesia, oral hypoesthesia, palmar-plantar erythrodysesthesia, oral paresthesia, genital hypoesthesia 34 0.3 Cognitive impairment Includes amnesia, aphasia, cognitive disorder, confusional state, delirium, disturbance in attention, hallucinations, visual hallucination, memory impairment, mental disorder, mental status changes 27 4.5 Peripheral sensory neuropathy Includes neuralgia, neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy 18 1.1 Headache 18 0.3 Ataxia Includes ataxia, balance disorder, gait disturbances 17 0.8 Sleep Includes hypersomnia, insomnia, sleep disorder, somnolence 14 0.6 Mood disorders Includes anxiety, affect lability, affective disorder, agitation, depressed mood, euphoric mood, mood altered, mood swings, irritability, depression, persistent depressive disorder, psychomotor retardation 10 0.6 Respiratory, Thoracic and Mediastinal Dyspnea 30 6 Cough 24 0.3 Musculoskeletal and Connective Tissue Myalgia Includes musculoskeletal pain, musculoskeletal chest pain, myalgia, neck pain 28 1.1 Arthralgia 21 0.6 Muscular weakness 12 0.8 Back pain 12 1 Pain in extremity 11 0.3 Metabolism and Nutritional Increased weight 25 7 Decreased appetite 13 0.3 Dehydration 10 1.1 Eye Vision disorders Includes blindness, cataract, cortical cataract, corneal erosion, diplopia, eye disorder, photophobia, photopsia, retinal hemorrhage, vision blurred, visual impairment, vitreous adhesions, vitreous detachment, vitreous floaters 21 0.8 Infections Urinary tract infection 13 2.3 Lung infection Includes lower respiratory tract infection, lung infection, pneumonia, respiratory tract infection 10 6 Vascular Hypotension Includes hypotension, orthostatic hypotension 18 2.8 Skin and Subcutaneous Tissue Rash Includes rash, rash maculopapular, rash pruritic, rash erythematous, rash papular 11 0.8 Clinically relevant adverse reactions occurring in ≤ 10% of patients include dysphagia (10%), fall (8%), pleural effusion (8%), fractures (6%), hypoxia (4.2%), pulmonary embolism (3.9%), syncope (3.9%), congestive heart failure (3.4%), and QTc prolongation (3.1%). Table 8 summarizes the laboratory abnormalities.

Table 8. Laboratory Abnormalities (≥ 20%) Worsening from Baseline in Patients Receiving ROZLYTREK in ALKA, STARTRK-1, STARTRK-2, and STARTRK-NG Laboratory Abnormality ROZLYTREK NCI CTCAE Grade All Grades (%) Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available which ranged from 111 to 346 patients.

Grade 3 or 4 (%) AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase Chemistry Increased creatinine Based on NCI CTCAE v5.0 73 2.1 Hyperuricemia 52 10 Increased AST 44 2.7 Increased ALT 38 2.9 Hypernatremia 35 0.9 Hypocalcemia 34 1.8 Hypophosphatemia 30 7 Increased lipase 28 10 Hypoalbuminemia 28 2.9 Increased amylase 26 5.4 Hyperkalemia 25 1.5 Increased alkaline phosphatase 25 0.9 Hyperglycemia NE = Not evaluable. Grade 1 and 2 could not be determined per NCI CTCAE v5.0, as fasting glucose values were not collected NE 3.8 Hematology Anemia 67 9 Lymphopenia 40 12 Neutropenia 28 7 Safety in Pediatric Patients The safety of ROZLYTREK was evaluated in pediatric patients with unresectable or metastatic solid tumors with a NTRK gene fusion enrolled in one of three multicenter, open-label clinical trials: STARTRK-NG (n=68), TAPISTRY (n=6) and STARTRK-2 (n=2).

Patients received ROZLYTREK 20 mg to 600 mg based on body surface area (BSA) orally or via enteral feeding tube once daily in 4-week cycles until unacceptable toxicity or disease progression. Among patients who received ROZLYTREK, 58% were exposed for 6 months or longer and 38% were exposed for greater than one year. The median age of patients who received ROZLYTREK was 6 years (range: 0 to 17); 51% were females; 68% were White, 18% Asian, 7% Black or African American, and 7% were other races.

Serious adverse reactions occurred in 45% of patients who received ROZLYTREK. Serious adverse reactions in > 2% of patients included skeletal fractures (12%), pneumonia (5%), pyrexia (5%), hydrocephalus (5%), device related infection (4%), hypoxia (4%), dyspnea (3%), headache (3%), gait disturbance (3%), pain (3%), upper respiratory infection (3%), and sepsis (3%).

Permanent discontinuation of ROZLYTREK due to an adverse reaction occurred in 13% of patients. Adverse reactions which resulted in permanent discontinuation of ROZLYTREK in > 2% of patients included skeletal fracture. Dosage interruptions of ROZLYTREK due to an adverse reaction occurred in 39% of patients. Adverse reactions which required dosage interruption in > 5% of patients included decreased neutrophil count, pyrexia, vomiting, and diarrhea.

Dose reductions of ROZLYTREK due to an adverse reaction occurred in 21% of patients. Adverse reactions which required dose reductions in > 2% of patients included increased blood creatinine and increased weight. Table 9 summarizes the adverse reactions in STARTRK-NG (n=68), TAPISTRY (n=6) and STARTRK-2 (n=2). Table 9. Adverse Reactions (≥20%) in Pediatric Patients Who Received ROZLYTREK in STARTRK-NG, TAPISTRY and STARTRK-2 Adverse Reaction ROZLYTREK (n=76) All Grades (%) Grade 3 or 4 (%) General Disorders Pyrexia 43 1.3 Fatigue Includes fatigue, asthenia 30 2.6 Gastrointestinal Disorders Constipation 41 1.3 Vomiting 38 0 Diarrhea 37 0 Nausea 34 0 Abdominal Pain 20 2.6 Investigations Increased Weight 39 18 Respiratory, Thoracic And Mediastinal Disorders Cough 33 1.3 Nasal Congestion 20 0 Musculoskeletal And Connective Tissue Disorders Pain in Extremity 26 2.6 Skeletal Fracture Includes clavicle fracture, tibia fracture, femur fracture, fibula fracture, foot fracture, fracture, pathological fracture, limb fracture, lower limb fracture, pelvic fracture, spinal compression fracture, stress fracture, ulna fracture 25 11 Metabolism And Nutrition Disorders Decreased Appetite 24 1.3 Nervous System Disorders Headache 22 2.6 Infections Upper Respiratory Tract Infection 20 1.3 Urinary Tract Infection 20 2.6 Clinically relevant adverse reactions in <20% of patients who received ROZLYTREK included pruritus, rash, urinary incontinence, eye pain and photophobia.

Tables 10 summarizes the laboratory abnormalities in STARTRK-NG (n=68), TAPISTRY (n=6) and STARTRK-2 (n=2). Table 10. Select Laboratory Abnormalities (≥20%) That Worsened from Baseline in Pediatric Patients Who Received ROZLYTREK in STARTRK-NG, TAPISTRY and STARTRK-2 Laboratory Abnormality ROZLYTREK The denominator used to calculate the rate varied from 67 to 76 based on the number of patients with a baseline value and at least one post-treatment value.

All values based on NCI CTCAE v5.0 All Grades (%) Grade 3 or 4 (%) AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase Hematology Decreased Hemoglobin 53 7 Decreased Neutrophils 53 22 Decreased Leukocytes 46 1.3 Increased Lymphocytes 33 3 Chemistry Increased Creatinine 84 5 Increased AST 61 2.7 Increased ALT 53 2.6 Increased Sodium 38 1.4 Increased Magnesium 32 5 Increased Alkaline Phosphatase 25 0 Decreased Glucose 26 0 Increased Potassium 25 2.7 Decreased Albumin 24 9 Increased Calcium 21 8 Increased Bilirubin 20 8 Other clinically relevant laboratory abnormalities in patients who received ROZLYTREK included decreased phosphorous.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ROZLYTREK. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiac Disorders: Brugada pattern and Brugada syndrome, including documented monomorphic ventricular tachycardia.

Adverse reaction frequency tables (US label) US FDA label
Table 7. Adverse Reactions (≥ 10%) in Patients Receiving ROZLYTREK in ALKA, STARTRK-1, STARTRK-2, and STARTRK-NG
Adverse Reactions ROZLYTREK n = 355
All Grades (%) Grade ≥ 3Grades 3 – 5, inclusive of fatal adverse reactions, including 2 events of pneumonia and 2 events of dyspnea. (%)
General
FatigueIncludes fatigue, asthenia 48 5
EdemaIncludes face edema, fluid retention, generalized edema, localized edema, edema, edema peripheral, peripheral swelling 40 1.1
Pyrexia 21 0.8
Gastrointestinal
Constipation 46 0.6
Diarrhea 35 2.0
Nausea 34 0.3
Vomiting 24 0.8
Abdominal painIncludes abdominal pain upper, abdominal pain, lower abdominal discomfort, abdominal tenderness 16 0.6
Nervous System
Dysgeusia 44 0.3
DizzinessIncludes dizziness, vertigo, dizziness postural 38 0.8
DysesthesiaIncludes paresthesia, hyperesthesia, hypoesthesia, dysesthesia, oral hypoesthesia, palmar-plantar erythrodysesthesia, oral paresthesia, genital hypoesthesia 34 0.3
Cognitive impairmentIncludes amnesia, aphasia, cognitive disorder, confusional state, delirium, disturbance in attention, hallucinations, visual hallucination, memory impairment, mental disorder, mental status changes 27 4.5
Peripheral sensory neuropathyIncludes neuralgia, neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy 18 1.1
Headache 18 0.3
AtaxiaIncludes ataxia, balance disorder, gait disturbances 17 0.8
SleepIncludes hypersomnia, insomnia, sleep disorder, somnolence 14 0.6
Mood disordersIncludes anxiety, affect lability, affective disorder, agitation, depressed mood, euphoric mood, mood altered, mood swings, irritability, depression, persistent depressive disorder, psychomotor retardation 10 0.6
Respiratory, Thoracic and Mediastinal
Dyspnea 30 6
Cough 24 0.3
Musculoskeletal and Connective Tissue
MyalgiaIncludes musculoskeletal pain, musculoskeletal chest pain, myalgia, neck pain 28 1.1
Arthralgia 21 0.6
Muscular weakness 12 0.8
Back pain 12 1
Pain in extremity 11 0.3
Metabolism and Nutritional
Increased weight 25 7
Decreased appetite 13 0.3
Dehydration 10 1.1
Eye
Vision disordersIncludes blindness, cataract, cortical cataract, corneal erosion, diplopia, eye disorder, photophobia, photopsia, retinal hemorrhage, vision blurred, visual impairment, vitreous adhesions, vitreous detachment, vitreous floaters 21 0.8
Infections
Urinary tract infection 13 2.3
Lung infectionIncludes lower respiratory tract infection, lung infection, pneumonia, respiratory tract infection 10 6
Vascular
HypotensionIncludes hypotension, orthostatic hypotension 18 2.8
Skin and Subcutaneous Tissue
RashIncludes rash, rash maculopapular, rash pruritic, rash erythematous, rash papular 11 0.8
Table 8. Laboratory Abnormalities (≥ 20%) Worsening from Baseline in Patients Receiving ROZLYTREK in ALKA, STARTRK-1, STARTRK-2, and STARTRK-NG
Laboratory Abnormality ROZLYTREK NCI CTCAE Grade
All Grades (%)Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available which ranged from 111 to 346 patients. Grade 3 or 4 (%)
AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase
Chemistry
Increased creatinineBased on NCI CTCAE v5.0 73 2.1
Hyperuricemia 52 10
Increased AST 44 2.7
Increased ALT 38 2.9
Hypernatremia 35 0.9
Hypocalcemia 34 1.8
Hypophosphatemia 30 7
Increased lipase 28 10
Hypoalbuminemia 28 2.9
Increased amylase 26 5.4
Hyperkalemia 25 1.5
Increased alkaline phosphatase 25 0.9
HyperglycemiaNE = Not evaluable. Grade 1 and 2 could not be determined per NCI CTCAE v5.0, as fasting glucose values were not collected NE 3.8
Hematology
Anemia 67 9
Lymphopenia 40 12
Neutropenia 28 7
Table 9. Adverse Reactions (≥20%) in Pediatric Patients Who Received ROZLYTREK in STARTRK-NG, TAPISTRY and STARTRK-2
Adverse Reaction ROZLYTREK (n=76)
All Grades (%) Grade 3 or 4 (%)
General Disorders
Pyrexia 43 1.3
FatigueIncludes fatigue, asthenia 30 2.6
Gastrointestinal Disorders
Constipation 41 1.3
Vomiting 38 0
Diarrhea 37 0
Nausea 34 0
Abdominal Pain 20 2.6
Investigations
Increased Weight 39 18
Respiratory, Thoracic And Mediastinal Disorders
Cough 33 1.3
Nasal Congestion 20 0
Musculoskeletal And Connective Tissue Disorders
Pain in Extremity 26 2.6
Skeletal FractureIncludes clavicle fracture, tibia fracture, femur fracture, fibula fracture, foot fracture, fracture, pathological fracture, limb fracture, lower limb fracture, pelvic fracture, spinal compression fracture, stress fracture, ulna fracture 25 11
Metabolism And Nutrition Disorders
Decreased Appetite 24 1.3
Nervous System Disorders
Headache 22 2.6
Infections
Upper Respiratory Tract Infection 20 1.3
Urinary Tract Infection 20 2.6
Table 10. Select Laboratory Abnormalities (≥20%) That Worsened from Baseline in Pediatric Patients Who Received ROZLYTREK in STARTRK-NG, TAPISTRY and STARTRK-2
Laboratory Abnormality ROZLYTREKThe denominator used to calculate the rate varied from 67 to 76 based on the number of patients with a baseline value and at least one post-treatment value. All values based on NCI CTCAE v5.0
All Grades (%) Grade 3 or 4 (%)
AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase
Hematology
Decreased Hemoglobin 53 7
Decreased Neutrophils 53 22
Decreased Leukocytes 46 1.3
Increased Lymphocytes 33 3
Chemistry
Increased Creatinine 84 5
Increased AST 61 2.7
Increased ALT 53 2.6
Increased Sodium 38 1.4
Increased Magnesium 32 5
Increased Alkaline Phosphatase 25 0
Decreased Glucose 26 0
Increased Potassium 25 2.7
Decreased Albumin 24 9
Increased Calcium 21 8
Increased Bilirubin 20 8

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on literature reports in humans with congenital mutations leading to changes in TRK signaling, findings from animal studies, and its mechanism of action [see Clinical Pharmacology (12.1)], ROZLYTREK can cause fetal harm when administered to a pregnant woman. There are no available data on ROZLYTREK use in pregnant women.

Administration of entrectinib to pregnant rats during the period of organogenesis resulted in malformations at maternal exposures approximately 2.7 times the human exposure at the 600 mg dose (see Data). Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data Human Data Published reports of individuals with congenital mutations in TRK pathway proteins suggest that decreases in TRK-mediated signaling are correlated with obesity, developmental delays, cognitive impairment, insensitivity to pain, and anhidrosis. Animal Data Entrectinib administration to pregnant rats during the period of organogenesis at a dose of 200 mg/kg [resulting in exposures up to 2.7 times the human exposure (AUC) at the 600 mg dose] resulted in maternal toxicity and fetal malformations including body closure defects (omphalocele and gastroschisis) and malformations of the vertebrae, ribs, and limbs (micromelia and adactyly), but not embryolethality.

Lower fetal weights and reduced skeletal ossification occurred at doses ≥ 12.5 and 50 mg/kg [approximately 0.2 and 0.9 times the human exposure (AUC) at the 600 mg dose], respectively.

Mechanism of action

12.1 Mechanism of Action Entrectinib is an inhibitor of the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC (encoded by the neurotrophic tyrosine receptor kinase [NTRK] genes NTRK1, NTRK2, and NTRK3, respectively), proto-oncogene tyrosine-protein kinase ROS1 (ROS1), and anaplastic lymphoma kinase (ALK) with IC 50 values of 0.1 to 2 nM. Entrectinib also inhibits JAK2 and TNK2 with IC 50 values > 5 nM.

The major active metabolite of entrectinib, M5, showed similar in vitro activity against TRK, ROS1, and ALK. Fusion proteins that include TRK, ROS1, or ALK kinase domains can drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation. Entrectinib demonstrated in vitro and in vivo inhibition of cancer cell lines derived from multiple tumor types harboring NTRK, ROS1, and ALK fusion genes.

Entrectinib demonstrated steady-state brain-to-plasma concentration ratios of 0.4 – 2.2 in multiple animal species (mice, rats, and dogs) and demonstrated in vivo anti-tumor activity in mice with intracranial implantation of TRKA- and ALK-driven tumor cell lines.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Entrectinib exposure-response relationships and the time course of pharmacodynamic responses are unknown. Cardiac Electrophysiology Across clinical trials, 3.1% of 355 patients, who received ROZLYTREK at doses ranging from 100 mg to 2600 mg daily under fasting or fed conditions (75% received 600 mg orally once daily) and had at least one postbaseline ECG assessment, experienced QTcF interval prolongation of > 60 ms after starting ROZLYTREK and 0.6% had a QTc interval > 500 ms [see Warnings and Precautions (5.2)].

At the maximum recommended ROZYLTREK dosage of 600 mg once daily, a small increase in mean QRS was observed [see Warnings and Precautions (5.2)].

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Excretion Following oral administration of a single oral dose of [ 14 C]-labeled entrectinib, 83% of radioactivity was excreted in feces (36% of the dose as unchanged entrectinib and 22% as M5) with minimal excretion in urine (3%).

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The pharmacokinetics for entrectinib and its pharmacologically active major circulating metabolite M5 were characterized in adult patients with ROS1 -positive NSCLC, NTRK gene fusion-positive solid tumors, and healthy subjects. The pharmacokinetics of entrectinib and M5 are linear and are not dose-dependent or time-dependent.

Steady state is achieved within one week for entrectinib and two weeks for M5 following daily administration of ROZLYTREK. The pharmacokinetic parameters for entrectinib and M5 are described in Table 11. Table 11. Pharmacokinetic Parameters for Entrectinib and Metabolite M5 Parameter Entrectinib Mean Geometric mean (% CV) M5 Mean (% CV) AUC D1 (nM*h) 31,800 (48%) 10,200 (82%) AUC ss (nM*h) 48,000 (77%) 24,000 (97%) C maxD1 (nM) 2,250 (58%) 622 (79%) C maxss (nM) 3,130 (80%) 1,250 (90%) R acc(AUC) 1.55 (49%) 2.84 (93%) Absorption The maximum entrectinib plasma concentration was reached 4 – 6 hours after oral administration of a 600 mg dose.

Entrectinib exposure following a single oral dose (600 mg) of ROZLYTREK oral pellets was not clinically significant compared to ROZLYTREK capsule administered with a light meal (250 calories: 25% fat) in healthy subjects. In STARTRK-2, STARTRK-NG and TAPISTRY studies, ROZLYTREK was administered without regard to food in patients.

Entrectinib exposure of a single dose (600 mg) of ROZLYTREK capsules as a suspension with water or milk, administered orally or through a nasogastric or gastric tube, was not clinically significant compared to administration of intact ROZLYTREK capsules in healthy subjects under fasted conditions. Effect of Food A high-fat (approximately 50% of total caloric content), high-calorie (approximately 800 to 1000 calories) meal did not have a significant effect on entrectinib exposure of ROZLYTREK capsules.

Distribution Entrectinib and its active major metabolite M5 are both > 99% bound to human plasma proteins in vitro. The estimated apparent volume of distribution (V/F) was 551 L and 81 L for entrectinib and M5, respectively. Elimination The estimated apparent clearance (CL/F) was 19.6 L/h and 52.4 L/h for entrectinib and M5, respectively.

The elimination half-lives of entrectinib and M5 were estimated to be 20 and 40 hours, respectively. Metabolism Entrectinib is metabolized primarily by CYP3A4 (~76%). The active metabolite M5 (formed by CYP3A4) is the only major active circulating metabolite identified. M5 has similar pharmacological potency to entrectinib in vitro and circulating M5 exposures at steady-state in patients were 40% of the corresponding entrectinib exposure.

Excretion Following oral administration of a single oral dose of [14 C]-labeled entrectinib, 83% of radioactivity was excreted in feces (36% of the dose as unchanged entrectinib and 22% as M5) with minimal excretion in urine (3%). Specific Populations No clinically significant differences in the pharmacokinetics of entrectinib were observed based on sex, race (White, Asian and Black), mild to moderate renal impairment (CLcr 30 to < 90 mL/min) and mild hepatic impairment (total bilirubin ≤ ULN with aspartate aminotransferase > ULN or total bilirubin > 1.0 – 1.5 times ULN with any aspartate aminotransferase).

The impact of severe renal impairment on the pharmacokinetics of entrectinib is unknown. Hepatic Impairment Following administration of a single oral dose of ROZLYTREK 100 mg (1/6 of the recommended dose), the entrectinib AUC INF was increased by 39% for the mild, 39% for the moderate, and 23% for the severe hepatic impairment groups compared to the normal hepatic function group.

The combined AUC last of entrectinib and M5 was increased by 16% for the mild, 16% for the moderate, and 4% for the severe hepatic impairment groups compared to the normal hepatic function group. Large variability in systemic exposure of entrectinib was observed in the hepatic impairment groups. Pediatric Patients > 6 months In pediatric patients older than 6 months administered 300 mg/m 2 (based on BSA) of ROZLYTREK once daily, systemic exposure of the sum of entrectinib and M5 in pediatric patients receiving 300 mg/m 2 of ROZLYTREK once daily is within the range of the adults treated with 600 mg of ROZLYTREK once daily.

The available efficacy and safety data also confirm the adequacy of the recommended doses [see Use in Specific Populations (8.4)]. Pediatric Patients > 1 to ≤ 6 months In pediatric patients > 1 to ≤ 6 months administered 250 mg/m 2 (based on BSA) of ROZLYTREK once daily, systemic exposure of the sum of entrectinib and M5 in pediatric patients was at the lower range of the adults administered 600 mg of ROZLYTREK once daily.

The available efficacy and safety data also confirm the adequacy of the recommended doses [see Use in Specific Populations (8.4)]. Drug Interaction Studies Clinical Studies Effect of CYP3A Inhibitors on Entrectinib: Coadministration of itraconazole (a strong CYP3A inhibitor) with a single 100 mg dose of ROZLYTREK capsule increased entrectinib AUC 0-INF by 6-fold and C max by 1.7-fold [see Drug Interactions (7.1)].

Coadministration of a moderate CYP3A inhibitor with ROZLYTREK capsule is predicted to increase entrectinib AUC 0-Tau by 3-fold and C max by 2.9-fold. Based on physiologically based pharmacokinetic (PBPK) modelling, a similar magnitude of the effect is expected in children as young as 2 years old. Effect of CYP3A Inducers on Entrectinib: Coadministration of rifampin (a strong CYP3A inducer) with a single 600 mg dose of ROZLYTREK capsule reduced entrectinib AUC 0-INF by 77% and C max by 56% [see Drug Interactions (7.1)].

Coadministration of a moderate CYP3A inducer with ROZLYTREK capsule is predicted to reduce entrectinib AUC 0-Tau by 56% and C max by 43%. Effect of Gastric Acid Reducing Drugs on Entrectinib: Coadministration of a proton pump inhibitor (PPI), lansoprazole with a single 600 mg dose of ROZLYTREK capsule reduced entrectinib AUC by 25% and C max by 23%.

Coadministration of lansoprazole, with a single 600 mg dose of ROZLYTREK capsule as oral suspension in water increased entrectinib AUC by 25% and C max by 17%. These changes are not likely to be clinically significant. Effect of Entrectinib on CYP Substrates: Coadministration of 600 mg dose of ROZLYTREK capsule once daily with oral midazolam (a sensitive CYP3A substrate) in patients increased the midazolam AUC by 50% but reduced midazolam C max by 21% [see Drug Interactions (7.1)].

Effect of Entrectinib on Transporters: Coadministration of a single 600 mg dose of ROZLYTREK capsule with digoxin [a sensitive P-glycoprotein (P-gp) substrate] increased digoxin C max by 28% and AUC by 18%. In Vitro Studies Entrectinib is not a substrate of P-gp or BCRP, but M5 is a substrate of P-gp and BCRP. Entrectinib and M5 are not substrates of OATP1B1 or OATP1B3.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Rozlytrek · Genentech, Inc. [US FDA-approved label, version 19, October 8, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7c71b0c-2549-4495-86b6-c2807fa54908
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .